Tower Research Capital LLC (Trc) Acurx Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.29 Billion
- Q1 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,411 shares of ACXP stock, worth $2,029. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,411
Previous 4,447
0.81%
Holding current value
$2,029
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ACXP
# of Institutions
28Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$940,4916.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$243,5000.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$168,6240.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$78,8840.0% of portfolio
-
Morgan Stanley New York, NY106KShares$48,8520.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $5.32M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...